A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
about
Probiotics and medical nutrition therapyIntestinal microbiota in functional bowel disorders: a Rome foundation reportProbiotic therapy for irritable bowel syndromeProbiotic effects on intestinal fermentation patterns in patients with irritable bowel syndromeDiagnosis and treatment of diarrhea-predominant irritable bowel syndromeGut microbiota role in irritable bowel syndrome: New therapeutic strategiesClinical Uses of ProbioticsUnraveling the ties between irritable bowel syndrome and intestinal microbiotaModulation of microbiota as treatment for intestinal inflammatory disorders: An uptodateThe interplay of the gut microbiome, bile acids, and volatile organic compoundsEfficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysisA randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulenceThe human microbiome and probiotics: implications for pediatricsAlpha-galactosidase versus active charcoal for improving sonographic visualization of abdominal organs in patients with excessive intestinal gasBritish Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults.A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndromeA probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.Treatment of functional bowel disorders: is there room for antibiotics?Effectiveness of probiotics in the treatment of irritable bowel syndrome.Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study.Effect of probiotics on symptoms in korean adults with irritable bowel syndrome.Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.Review article: the treatment of functional abdominal bloating and distension.A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life.A pilot study on the effect of a symbiotic mixture in irritable bowel syndrome: an open-label, partially controlled, 6-month extension of a previously published trial.New onset of constipation during long-term physical inactivity: a proof-of-concept study on the immobility-induced bowel changes.Probiotics and irritable bowel syndrome.Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic DichotomyGas and Bloating.The Emerging Therapeutic Role of Medical Foods for Gastrointestinal Disorders.Vitamin D/VDR, Probiotics, and Gastrointestinal DiseasesLactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formationLower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort.Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissueThe efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trialTherapeutic effects of biobran, modified arabinoxylan rice bran, in improving symptoms of diarrhea predominant or mixed type irritable bowel syndrome: a pilot, randomized controlled study.The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial.Bacterial probiotic modulation of dendritic cells.Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP
P2860
Q24548441-FB76A1E7-AD09-4654-A2F2-D3FD56C8E269Q24631357-887D7A82-A49D-4E67-B895-54D25165F0A7Q24633694-3D59658D-BC0C-4EAE-92AF-E70E467FF36DQ24655815-77C96B63-3881-4CA6-BAA3-820370B0DE69Q26765272-8A212CE4-FC32-4CD4-8820-E6E5D66731E1Q26768550-6C475615-6BB3-4448-AEF9-D5C3B8FF7EAFQ26769032-7D1D0D31-33B5-47D4-82F5-28991B7C7FC9Q27004645-A8ED365D-3181-457C-BD1F-4BCD098F2C72Q28072437-C1799602-3AE4-4624-9340-33A39D2957DBQ28082012-95CD029A-D12A-4259-824B-0DAEE6D1E552Q28244815-81377457-775C-4963-B40B-EC52A11027E7Q28295210-C312C91A-E055-4066-8C37-7101AFDC3A4BQ28750959-70294B19-A03E-41A7-A09D-6B1307DC4863Q30534672-2A88A327-E13F-4447-B09F-98650A5A0ABBQ31054269-8A5F0F23-3183-46CE-BC38-49AA1F7DCF0EQ33409756-EC88290C-F805-44C2-9D9E-8D29545583D5Q33433931-56A60845-F9D8-4EF6-BEE8-62F9E39743B0Q33434046-AF0E0F99-DAB7-4314-81D8-5571251FEF45Q33434853-21EC9EEB-B29D-4248-BC45-B5985F2D7128Q33439491-E4BBF8F5-0AA8-4921-A702-8026E0ABADB7Q33443147-BB03D056-54A6-4CC2-8B54-D765D9E34A96Q33446254-B9AB57D2-0F73-4270-8812-81CD4412AB0DQ33449885-1E61E6E3-E965-4CD5-AA97-7C8B901FFD25Q33450132-9A24B941-5D91-47B5-8320-5E4010F296B2Q33455506-9C031FA5-CA8D-4C10-8D43-28D960261F8AQ33458837-0125600D-75FA-4B89-86BB-86851CC0201FQ33459003-B450BD6F-418F-4A2D-8AB0-76B5FE81193DQ33459043-19C2EC16-89BF-428B-8826-C2DA098A58CAQ33469991-9F7A0901-C0EF-44BB-99B5-B8829A162DFAQ33470091-0ECB8A3F-BF3F-4BEA-BC5F-6C6736F727CBQ33595797-4FC0BBB4-2D6F-4729-9DA1-9400AAA127C3Q33758617-AA45EAA1-529F-438B-836F-5BFE12D8C88DQ33767034-1DE8C360-8DF5-4C79-A0A3-AC42A587DB89Q33780866-0D627185-15A6-45CB-BA68-A3D5774C6CC2Q34013048-54927442-6A44-4FB3-84F6-D0291CAB6A4CQ34031406-63AAFBD1-E716-4AB3-9356-998A7635EC5BQ34069833-D8ED571F-6066-4E59-A99F-6A07B3F7D235Q34072873-7ED49BF6-E2AA-44A1-9238-B79314CBAA62Q34144168-B5F0D9B2-6495-4F90-8E9F-84CA83694E71Q34155897-ADC4F5FC-1EEB-4252-B640-0BC153BD9F58
P2860
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
A randomized controlled trial ...... nant irritable bowel syndrome.
@en
A randomized controlled trial ...... nant irritable bowel syndrome.
@nl
type
label
A randomized controlled trial ...... nant irritable bowel syndrome.
@en
A randomized controlled trial ...... nant irritable bowel syndrome.
@nl
prefLabel
A randomized controlled trial ...... nant irritable bowel syndrome.
@en
A randomized controlled trial ...... nant irritable bowel syndrome.
@nl
P2093
P2860
P1476
A randomized controlled trial ...... nant irritable bowel syndrome.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2036.2003.01543.X
P407
P577
2003-04-01T00:00:00Z